在老年痴呆症、帕金森症2种疾病的新药开发中，已经用到了26个iPS细胞。该技术有望大幅降低创药费用的本领域，与致力于确保试验人数的欧美相比，有助于通过使用多样的试验研究用细胞来减轻创药成本，加强国际竞争力。创药成本的降低，也意味着医药费用的削减。业内人士认为，通过此次的规制改革，不仅可以期待新的医药品的开发，还有助于提高药效评价和安全性评价的精度，是有用的措施。
26 iPS cells have been used in the development of new drugs forAlzheimer's disease and Parkinson's disease. This technology isexpected to significantly reduce the cost of drug creation in thisfield. Compared with Europe and the United States, which arecommitted to ensuring the number of trials, it will help to reducethe cost of drug creation by using a variety of cells forexperimental research and strengthen international competitiveness.The reduction in the cost of creating drugs also means thereduction of medical expenses. Industry insiders believe thatthrough this regulatory reform, not only the development of newpharmaceuticals can be expected, but also the improvement of theaccuracy of drug efficacy and safety evaluations is a usefulmeasure.